Edwards LifesciencesEWEarnings & Financial Report
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
EW Q3 2025 Key Financial Metrics
Revenue
$1.6B
Gross Profit
$1.2B
Operating Profit
$307.1M
Net Profit
$291.1M
Gross Margin
77.8%
Operating Margin
19.8%
Net Margin
18.7%
YoY Growth
14.7%
EPS
$0.50
Financial Flow
Edwards Lifesciences Q3 2025 Financial Summary
Edwards Lifesciences reported revenue of $1.6B for Q3 2025, with a net profit of $291.1M (18.7% margin). Cost of goods sold was $345.2M, operating expenses totaled $900.8M.
Key Financial Metrics
| Total Revenue | $1.6B |
|---|---|
| Net Profit | $291.1M |
| Gross Margin | 77.8% |
| Operating Margin | 19.8% |
| Report Period | Q3 2025 |
Edwards Lifesciences Annual Revenue by Year
Edwards Lifesciences annual revenue history includes year-by-year totals (for example, 2024 revenue was $5.7B).
| Year | Annual Revenue |
|---|---|
| 2024 | $5.7B |
| 2023 | $5.7B |
| 2022 | $5.4B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.27B | $1.60B | $1.39B | $1.35B | $1.39B | $1.41B | $1.53B | $1.55B |
| YoY Growth | -6.1% | 9.5% | -9.4% | -8.5% | 9.4% | -11.6% | 10.6% | 14.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $9.36B | $9.74B | $10.10B | $12.97B | $13.06B | $13.02B | $13.49B | $13.27B |
| Liabilities | $2.64B | $2.55B | $2.59B | $3.36B | $2.99B | $2.83B | $2.88B | $3.07B |
| Equity | $6.65B | $7.12B | $7.44B | $9.55B | $10.00B | $10.13B | $10.55B | $10.21B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $136.6M | $-53.5M | $371.5M | $351.8M | $-127.5M | $280.4M | $290.2M | $573.7M |
Other Health Care Companies
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M
BSX
Boston Scientific
Revenue
$5.3B
Net Profit
$670.0M
DXCM
Dexcom
Revenue
$1.3B
Net Profit
$267.3M
GEHC
GE HealthCare
Revenue
$5.7B
Net Profit
$588.0M
HOLX
Hologic
Revenue
$1.0B
Net Profit
$179.1M
IDXX
Idexx Laboratories
Revenue
$1.1B
Net Profit
$274.6M
PODD
Insulet Corporation
Revenue
$783.7M
Net Profit
$101.6M
ISRG
Intuitive Surgical
Revenue
$2.9B
Net Profit
$794.8M